Dermatológia pre prax 2/2024

Overview of biological therapies for the treatment of hidradenitis suppurativa with a focus on bimekizumab

Hidradenitis suppurativa is chronic inflammatory skin disease affecting hair follicles, with profoundly negative impact on patient quality of life. Our paper presents options for biological treatment of HS with a focus on bimkekizumab. Bimekizumab, a dual inhibitor of interleukins IL-17A and IL-17F, has been approved by the European Medicines Agency for the treatment of active, moderate to severe hidradenitis suppurativa (acne inversa) in adults who have not responded adequately to conventional systemic HS therapy. In this article, we provide an overview of the basic results from the BE HEARD I and II studies.

Keywords: hidradenitis suppurativa, biological treatment, bimekizumab, BE HEARD I a II